Right Turn: Out of the bubble with gene-edited stem cells

Author: Lisa Willemse, 11/21/14

> This is a rather exciting time to be in the stem cell and regenerative medicine field and one of the main reasons for this is the number of announcements and articles about clinical trials taking place. Seven years ago, when I joined the Stem Cell Network, these were a rare occurrence, but today it’s…Read more

Lessons from Dendreon

Author: Mark Curtis, 11/20/14

. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its senior debt holders, its fate remains unclear and could include…Read more

If cell therapy isn’t about the cells or the therapy, what is it about?

Author: David Brindley, 11/19/14

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate.   Both the IBC Cell Therapy Bioprocessing (ICTB) conference and the Stem Cells and Regenerative Medicine Congress (SCRMC) took place recently. The conferences shared several common themes: one being the presence of a significant focus…Read more

Right Turn: “Changing the face of men’s health” (one moustache at a time)

Author: Stacey Johnson, 11/14/14

. The month of November can mean different things to different people. For example, Canadians recognize Remembrance Day on November 11, Americans have Veterans Day and my Polish friends celebrate National Independence Day. There’s American Thanksgiving immediately followed by the countdown to how many shopping days are left until Christmas. Today, as it turns out,…Read more

Revolution and reimbursement in the cell therapy industry

Author: David Brindley, 11/13/14

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate   In the early 1770s, Britain faced a significant financial dilemma. One of its most important commercial institutions, the East India Company, had come into considerable financial problems; a large quantity of tea was being…Read more

Cell Therapy Commercialization: A View from Lonza on Bioreactors

Author: Mark Curtis, 11/10/14

. I had the pleasure of meeting Dr. Eytan Abraham over lunch on the first day of the Till & McCulloch Meetings, held last month in Ottawa (October 27-29). After some discussion about cell therapy manufacturing, I learned that he is the new Head of Research and Technology at Lonza, based out of Walkersville, Maryland….Read more

Right Turn: Seeing the potential of retinal stem cells

Author: Ben Paylor, 11/07/14

> The well known expression that “the eyes are the gateway to the soul” has tragic connotations in the context of retinal disease. Rhetoric aside, the potential for regenerative medicine to improve our ability to treat ocular disease and injury makes it an exciting area of stem cell research. It is also one that has…Read more

Cell Therapy Commercialization: A View from GE Healthcare on Immunotherapy

Author: Mark Curtis, 11/04/14

. Those following the regenerative medicine (RM) industry are likely in-tune with a rapidly evolving market, on the periphery, that is shaping up to provide a very attractive value proposition to patients, industry, and investors alike. The health care industry is undergoing a paradigm shift: Big Pharma has historically spread its efforts across palliative and substitutive…Read more

Right Turn: A Halloween gift that keeps on giving (and we’re not talking about cloning)

Author: Stacey Johnson, 10/31/14

. Hobgoblins, hocus pocus, hayrides and haunted houses…Happy Halloween! Do those words conjure up a feeling of dread or does a wave of happiness wash over you when you hear Happy Halloween? Perhaps more relevant here, does the word Halloween ever make you think of stem cells? Stem cells and Halloween don’t typically go together…Read more

Trainee talks – where you hear about the really cool stuff

Author: David Kent, 10/30/14

> One of the consistent themes of the Till and McCulloch Meetings (#TMM2014) is its commitment to having students and postdocs on stage presenting their work. These sessions have been regularly cited by my colleagues as the most interesting and engaging sessions with the most new data. The last few meetings they have called these…Read more